IO Biotech, Inc. (IOBT)
Market: NASD |
Currency: USD
Address: Ole Maaløes Vej 3
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Show more
📈 IO Biotech, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$9.50
-
Upside/Downside from Analyst Target:
619.70%
-
Broker Call:
10
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
10-25%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for IO Biotech, Inc.
| Date | Reported EPS |
|---|
| 2025-05-14 | -0.34 |
| 2025-03-31 | -0.48 |
| 2024-11-12 | -0.36 |
| 2024-08-13 | -0.31 |
| 2024-08-12 | -0.31 |
| 2024-05-14 | -0.3 |
| 2024-05-13 | -0.3 |
| 2024-03-05 | -0.4 |
| 2024-03-04 | -0.4 |
| 2023-11-13 | -0.43 |
| 2023-11-12 | -0.43 |
| 2023-08-11 | -0.74 |
| 2023-08-10 | -0.74 |
| 2023-05-11 | -0.59 |
| 2023-05-10 | -0.59 |
| 2023-03-14 | -0.7 |
| 2023-03-13 | -0.7 |
| 2022-11-09 | -0.56 |
| 2022-11-08 | -0.56 |
| 2022-08-11 | -0.64 |
| 2022-08-10 | -0.64 |
| 2022-05-16 | -0.6 |
| 2022-05-15 | -0.6 |
| 2022-03-31 | - |
| 2022-03-30 | - |
| 2021-12-17 | -36.88 |
| 2021-12-16 | -36.88 |
| 2021-11-08 | - |
| 2021-11-07 | - |
📰 Related News & Research
No related articles found for "io biotech".
